bpc 157 canlab BPC-157 VIAL - High Purity Laboratory Research Peptide BPC-157 (10mg) – Canlab International

Response: Although we acknowledge the applicant's concerns regarding the descriptor for C1739, we do not agree that the device category code should be withdrawn and replaced with a new code effective January 1, 2026, for the following reasons: First, per the applicant's request prior to CY 2026 rulemaking, CMS revised the descriptor for C1739 to read, effective October 1, 2025: Tissue marker, uniquely detectable and identifiable with probe/sensor, any method (implantable), with delivery system

Available Strengths: 5 mg 10 mg

Other types of NSAIDs include ibuprofen, naproxen, and high-dose aspirin

Legal battle involving peptide restrictions The backstory: A legal challenge spearheaded by EVEXIAS Life Sciences is actively fighting the FDA's placement of 17 peptides on its restrictive "Category 2" list, which effectively bans compounding pharmacies from making them under the claim that they are unsafe